

COSTEM 2023 – Program Template

Thursday, October 19

15:30-17:00	<i>Industry session timeslot</i>
17:00-17:30	<i>Coffee Break</i>
17:30-18:30	<i>Industry session timeslot / MTE timeslots (30-min sessions)</i>
18:30	Welcome Reception

Friday, October 20

	Hall A	
08:30-09:30	<i>Industry session timeslot (Pre-congress session / workshop)</i>	
09:30-09:45	<i>Short Break</i>	
09:45-09:55	Welcome note: Nicolaus Kröger, Germany and Arnon Nagler, Israel	
09:55-11:30	Opening Session: BiTE vs CAR T	
09:55-10:25	Controversy: BiTE vs CAR T in post Auto Rel/Ref MM Moderator: Arnon Nagler, Israel	
09:55-10:10	Pro BiTE: Philippe Moreau, France	
10:10-10:25	Pro CAR: Nikhil Munshi, USA	
10:25-10:55	Controversy: BiTE vs CAR T in DLBCL Moderator: Nicolaus Kröger, Germany	
10:25-10:40	Pro BiTE: <i>TBA</i>	
10:40-10:55	Pro CAR T: Michael Bishop, USA	
10:55-11:15	Panel discussion: <i>All</i>	
11:15-11:45	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
	Hall A	Hall B
11:45-13:15	Session 1: AML	Session 2: MDS
11:45-12:15	Controversy: Do we need MRD negativity pre Allo in AML? Moderator: Charles Craddock, UK	Controversy: Should we perform a transplant in MDS pts with p53? Moderator: Avichai Shimoni, Israel
11:45-12:00	Yes: Christopher Hourigan, USA	Yes: Bart Lee Scott, USA
12:00-12:15	No: Michael Heuser, Germany	No: <i>TBA</i>
12:15-12:45	Controversy: Is there a role for salvage therapy pre Allo in refractory/ relapsed AML? Moderator: Arnon Nagler, Israel	Controversy: Are there patients with low IPSSR who benefit from early transplant? Moderator: Alessandro Rambaldi, Italy
12:15-12:30	Yes: Charles Craddock, UK	Yes: Ibrahim Yakoub-Agha, France
12:30-12:45	No: Johannes Schetelig, Germany	No: <i>TBA</i>
12:45-13:15	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
13:15-13:30	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>	

13:30-14:30	<i>Industry session timeslot (Hall A)</i>	
14:30-14:45	<i>Short Break</i>	
14:45-16:15	<b>Session 3: Allogeneic transplantation</b>	<b>Session 4: Lymphoma</b>
14:45-15:15	<b>Controversy: Is treosulfan conditioning the new standard for allogeneic SCT in MDS?</b> Moderator: <b>Bart Lee Scott</b> , USA	<b>Controversy: Is there still a role for Auto transplant in MCL?</b> Moderator: <b>Ali Bazarbachi</b> , Lebanon
14:45-15:00	Yes: <b>Avichai Shimoni</b> , Israel	Yes: <i>TBA</i>
15:00-15:15	No: <b>Alessandro Rambaldi</b> , Italy	No: <i>TBA</i>
15:15-15:45	<b>Controversy: Are venetoclax combinations replacing anthracycline/ARAC containing induction regimen prior to allogeneic stem cell transplantation?</b> Moderator: <i>TBA</i>	<b>Controversy: Is there is still a role for Allo transplant in Hodgkin lymphoma?</b> Moderator: <i>TBA</i>
15:15-15:30	Yes: <i>TBA</i>	Yes: <b>Ali Bazarbachi</b> , Lebanon
15:30-15:45	No: <i>TBA</i>	No: <i>TBA</i>
15:45-16:15	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
16:15-16:45	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>	
16:45-17:45	<i>Industry session timeslot (Hall A)</i>	
17:45-18:00	<i>Short Break</i>	
18:00-19:30	<b>Session 5: GvHD</b>	<b>Session 6: MPN</b>
18:00-18:30	<b>Controversy: is PTCy/MMF/CNI or ATG/MMF/CNI the standard of care GvHD prophylaxis in MUD?</b> Moderator: <b>Corey Cutler</b> , USA	<b>Controversy: Should patients be monitored post Allo with molecular markers?</b> Moderator: <i>TBA</i>
18:00-18:15	PTCy: <b>Leonido Luznik</b> , USA	Yes: <b>Nicolaus Kröger</b> , Germany
18:15-18:30	ATG: <b>Francesca Bonifazi</b> , Italy	No: <i>TBA</i>
18:30-19:00	<b>Controversy: Are JAK inhibitors the new standard for all SR acute and chronic GvHD manifestations?</b> Moderator: <b>Leonido Luznik</b> , USA	<b>Controversy: Should KRAS or others be added to ASXL1, SRSF2 and EZH2 as bad predictors indicating transplants in myelofibrosis?</b> Moderator: <i>TBA</i>
18:30-18:45	Yes: <b>Robert Zeiser</b> , Germany	Yes: <b>Nico Gagelmann</b> , Germany
18:45-19:00	No: <b>Corey Cutler</b> , USA	No: <i>TBA</i>
19:00-19:30	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>
19:30-20:30	<b>Poster Walk Session</b> <i>at the Poster Area</i>	

**Saturday, October 21**

Hall A		Hall B	
<b>08:30-10:00</b>	<b>Session 7: Donor selection</b>	<b>Session 8: Haploidentical transplants</b>	
08:30-09:00	<b>Controversy: Is selecting according to HLA including HLA B leader and permissive MM for Allogeneic transplants in the era of PTCy still needed?</b> Moderator: <b>Robert Soiffer</b> , USA	<b>Controversy: Does PTCy increase late relapses and late infections post haploidentical transplants?</b> Moderator: <b>Bart Lee Scott</b> , USA	
08:30-08:45	Yes: <b>Katharina Fleischhauer</b> , Germany	Yes: <i>TBA</i>	
08:45-09:00	No: <b>Bronwen Shaw</b> , USA	No: <b>Christopher Kanakry</b> , USA	
09:00-09:30	<b>Controversy: Is younger MUD better than HLA-sibling in older MDS and AML patients?</b> Moderator: <b>Bronwen Shaw</b> , USA	<b>Controversy: Does PTCy in Haplo transplant for children replace ex vivo T cell depletion?</b> Moderator: <i>TBA</i>	
09:00-09:15	Yes: <b>Wael Saber</b> , USA	Yes: <b>Michael Pulsipher</b> , USA	
09:15-09:30	No: <b>Robert Soiffer</b> , USA	No: <b>Peter Bader</b> , Germany	
09:30-10:00	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>	
<b>10:00-10:30</b>	<i>Coffee Break, Poster Viewing and Visit Exhibition</i>		
<b>10:30-11:30</b>	<i>Industry session timeslot (Hall A)</i>		
<b>11:30-11:45</b>	<i>Short Break</i>		
<b>11:45-13:15</b>	<b>Session 9: Immunotherapy I</b>	<b>Session 10: ALL</b>	
11:45-12:15	<b>Controversy: Did we progress with CAR T in AML?</b> Moderator: <b>David Porter</b> , USA	<b>Controversy: Are we ready to abandon Allo in ALL?</b> Moderator: <b>Matthias Stelljes</b> , Germany	
11:45-12:00	Yes: <b>Saar Gill</b> , USA	Yes: <i>TBA</i>	
12:00-12:15	No: <b>Marion Subklewe</b> , Germany	No: <b>Arnon Nagler</b> , USA	
12:15-12:45	<b>Controversy: TCR editing vs CAR in malignancies</b> Moderator: <b>Marion Subklewe</b> , Germany	<b>Controversy: Do we need Allo post CAR in ALL?</b> Moderator: <b>Ibrahim Yakoub-Agha</b> , France	
12:15-12:30	Pro TCR: <b>Chiara Bonini</b> , Italy	Yes: <b>Peihua Lu</b> , China	
12:30-12:45	Pro CAR: <b>David Porter</b> , USA	No: <i>TBA</i>	
12:45-13:15	Panel discussion: <i>All</i>	Panel discussion: <i>All</i>	
<b>13:15-13:30</b>	<i>Lunch Pick-up, Poster Viewing and Visit Exhibition</i>		
<b>13:30-15:00</b>	<i>Industry session timeslot (Hall A)</i>		
<b>15:00-15:15</b>	<i>Short Break</i>		
<b>15:15-16:45</b>	<b>Session 11: Immunotherapy II</b>	<b>Session 12: Pediatric and non-malignancies</b>	
15:15-15:45	<b>Controversy: Are CAR T cells replacing autologous SCT in Autoimmune disease?</b> Moderator: <b>Nicolaus Kröger</b> , Germany	<b>Controversy: SCT vs gene therapy in sickle cell anemia and thalassemia</b> Moderator: <b>Selim Corbacioglu</b> , Germany	
15:15-15:30	Yes: <b>Dominique Farge</b> , France	15:15-15:30 - SCT: <b>Suradeej Hongeng</b> , Thailand	
15:30-15:45	No: <b>Riccardo Saccardi</b> , Italy	15:30-15:45 - Gene therapy: <i>TBA</i>	
		15:45-16:00 - Discussion	

15:45-16:15	Controversy: Is point of care production of CAR T cell the favorable way to go forward? Moderator: <b>Claudio Cerchione</b> , Italy	Controversy: SCT vs gene therapy in inborn errors Moderator: <b>Peter Bader</b> , Germany
15:45-16:00	Yes: <b>Stephan Mielke</b> , Sweden	16:00-16:15 - SCT: <b>Arjan Lankester</b> , Netherlands
16:00-16:15	No: <i>TBA</i>	16:15-16:30 - Gene therapy: <b>Selim Corbacioglu</b> , Germany
16:15-16:45	Panel discussion: <i>All</i>	16:30-16:45 - Discussion
16:45	Closing remarks: <b>Nicolaus Kröger</b> , Germany and <b>Arnon Nagler</b> , Israel	